Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
AIRS vs INMD vs SKIN vs NVCR vs ISRG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Household & Personal Products
Medical - Instruments & Supplies
Medical - Instruments & Supplies
AIRS vs INMD vs SKIN vs NVCR vs ISRG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Devices | Household & Personal Products | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $216M | $882M | $118M | $1.92B | $161.07B |
| Revenue (TTM) | $158M | $375M | $296M | $674M | $10.58B |
| Net Income (TTM) | $-18M | $87M | $-6M | $-173M | $2.98B |
| Gross Margin | 64.0% | 77.8% | 64.9% | 75.2% | 66.3% |
| Operating Margin | -9.3% | 21.3% | -3.6% | -27.2% | 30.5% |
| Forward P/E | — | 9.6x | — | — | 43.8x |
| Total Debt | $105M | $13M | $379M | $290M | $303M |
| Cash & Equiv. | $8M | $303M | $233M | $103M | $3.37B |
AIRS vs INMD vs SKIN vs NVCR vs ISRG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Oct 21 | May 26 | Return |
|---|---|---|---|
| AirSculpt Technolog… (AIRS) | 100 | 21.8 | -78.2% |
| InMode Ltd. (INMD) | 100 | 14.7 | -85.3% |
| The Beauty Health C… (SKIN) | 100 | 3.3 | -96.7% |
| NovoCure Limited (NVCR) | 100 | 16.4 | -83.6% |
| Intuitive Surgical,… (ISRG) | 100 | 125.6 | +25.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AIRS vs INMD vs SKIN vs NVCR vs ISRG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AIRS is the #2 pick in this set and the best alternative if dividends and momentum is your priority.
- 0.1% yield; the other 4 pay no meaningful dividend
- +35.2% vs SKIN's -35.9%
INMD ranks third and is worth considering specifically for valuation efficiency.
- PEG 0.97 vs ISRG's 2.01
- Lower P/E (9.6x vs 43.8x), PEG 0.97 vs 2.01
SKIN lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
ISRG carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.02
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 5.5% 10Y total return vs INMD's 105.0%
- Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs SKIN's -10.0% | |
| Value | Lower P/E (9.6x vs 43.8x), PEG 0.97 vs 2.01 | |
| Quality / Margins | 28.2% margin vs NVCR's -25.7% | |
| Stability / Safety | Beta 1.02 vs AIRS's 3.37, lower leverage | |
| Dividends | 0.1% yield; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +35.2% vs SKIN's -35.9% | |
| Efficiency (ROA) | 14.8% ROA vs NVCR's -16.5%, ROIC 15.0% vs -16.4% |
AIRS vs INMD vs SKIN vs NVCR vs ISRG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
AIRS vs INMD vs SKIN vs NVCR vs ISRG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 3 of 6 categories
INMD leads 1 • AIRS leads 0 • SKIN leads 0 • NVCR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ISRG is the larger business by revenue, generating $10.6B annually — 67.2x AIRS's $158M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $158M | $375M | $296M | $674M | $10.6B |
| EBITDAEarnings before interest/tax | -$2M | $81M | $9M | -$165M | $3.8B |
| Net IncomeAfter-tax profit | -$18M | $87M | -$6M | -$173M | $3.0B |
| Free Cash FlowCash after capex | $2M | $91M | $29M | -$48M | $2.8B |
| Gross MarginGross profit ÷ Revenue | +64.0% | +77.8% | +64.9% | +75.2% | +66.3% |
| Operating MarginEBIT ÷ Revenue | -9.3% | +21.3% | -3.6% | -27.2% | +30.5% |
| Net MarginNet income ÷ Revenue | -11.4% | +23.3% | -2.0% | -25.7% | +28.2% |
| FCF MarginFCF ÷ Revenue | +1.6% | +24.2% | +9.8% | -7.1% | +26.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -17.8% | +5.3% | -6.7% | +12.3% | +23.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -50.0% | -30.8% | +38.0% | -100.0% | +18.8% |
Valuation Metrics
INMD leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 9.7x trailing earnings, INMD trades at a 83% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), INMD offers better value at 0.98x vs ISRG's 2.65x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $216M | $882M | $118M | $1.9B | $161.1B |
| Enterprise ValueMkt cap + debt − cash | $313M | $593M | $264M | $2.1B | $158.0B |
| Trailing P/EPrice ÷ TTM EPS | -24.71x | 9.73x | -5.69x | -13.80x | 57.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 9.64x | — | — | 43.84x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.98x | — | — | 2.65x |
| EV / EBITDAEnterprise value multiple | 31.06x | 6.88x | 7331.15x | — | 43.62x |
| Price / SalesMarket cap ÷ Revenue | 1.20x | 2.38x | 0.39x | 2.92x | 16.00x |
| Price / BookPrice ÷ Book value/share | 2.52x | 1.33x | 2.02x | 5.51x | 9.17x |
| Price / FCFMarket cap ÷ FCF | — | 10.46x | 3.17x | — | 64.67x |
Profitability & Efficiency
ISRG leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-51 for NVCR. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SKIN scores 7/9 vs AIRS's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -21.8% | +13.3% | -9.4% | -50.8% | +16.9% |
| ROA (TTM)Return on assets | -9.0% | +11.8% | -1.2% | -16.5% | +14.8% |
| ROICReturn on invested capital | -0.8% | +13.5% | -6.8% | -16.4% | +15.0% |
| ROCEReturn on capital employed | -1.0% | +12.1% | -4.5% | -28.9% | +16.5% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 | 7 | 5 | 6 |
| Debt / EquityFinancial leverage | 1.32x | 0.02x | 6.20x | 0.85x | 0.02x |
| Net DebtTotal debt minus cash | $97M | -$289M | $146M | $187M | -$3.1B |
| Cash & Equiv.Liquid assets | $8M | $303M | $233M | $103M | $3.4B |
| Total DebtShort + long-term debt | $105M | $13M | $379M | $290M | $303M |
| Interest CoverageEBIT ÷ Interest expense | -1.82x | — | 0.81x | -96.80x | — |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $707 for SKIN. Over the past 12 months, AIRS leads with a +35.2% total return vs SKIN's -35.9%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs SKIN's -56.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +87.0% | -5.9% | -35.0% | +28.3% | -19.3% |
| 1-Year ReturnPast 12 months | +35.2% | -2.1% | -35.9% | +1.1% | -15.4% |
| 3-Year ReturnCumulative with dividends | -34.0% | -60.2% | -91.7% | -75.7% | +49.6% |
| 5-Year ReturnCumulative with dividends | -75.6% | -63.9% | -92.9% | -91.3% | +58.7% |
| 10-Year ReturnCumulative with dividends | -75.6% | +105.0% | -91.6% | +30.3% | +554.2% |
| CAGR (3Y)Annualised 3-year return | -12.9% | -26.4% | -56.4% | -37.6% | +14.4% |
Risk & Volatility
Evenly matched — NVCR and ISRG each lead in 1 of 2 comparable metrics.
Risk & Volatility
ISRG is the less volatile stock with a 1.02 beta — it tends to amplify market swings less than AIRS's 3.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs AIRS's 28.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.37x | 1.04x | 2.00x | 2.20x | 1.02x |
| 52-Week HighHighest price in past year | $12.00 | $16.74 | $2.69 | $20.06 | $603.88 |
| 52-Week LowLowest price in past year | $1.51 | $12.72 | $0.76 | $9.82 | $427.84 |
| % of 52W HighCurrent price vs 52-week peak | +28.8% | +83.2% | +33.8% | +83.9% | +75.1% |
| RSI (14)Momentum oscillator 0–100 | 70.0 | 39.8 | 52.1 | 69.8 | 42.4 |
| Avg Volume (50D)Average daily shares traded | 3.1M | 804K | 760K | 1.5M | 1.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: AIRS as "Hold", INMD as "Buy", SKIN as "Hold", NVCR as "Buy", ISRG as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 14.9% for INMD (target: $16). AIRS is the only dividend payer here at 0.13% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $6.00 | $16.00 | $1.30 | $33.50 | $622.60 |
| # AnalystsCovering analysts | 5 | 11 | 13 | 15 | 55 |
| Dividend YieldAnnual dividend ÷ price | +0.1% | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | — | — |
| Dividend / ShareAnnual DPS | $0.00 | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.4% | +14.5% | 0.0% | 0.0% | +1.4% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). INMD leads in 1 (Valuation Metrics). 1 tied.
AIRS vs INMD vs SKIN vs NVCR vs ISRG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AIRS or INMD or SKIN or NVCR or ISRG a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). InMode Ltd. (INMD) offers the better valuation at 9. 7x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate InMode Ltd. (INMD) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AIRS or INMD or SKIN or NVCR or ISRG?
On trailing P/E, InMode Ltd.
(INMD) is the cheapest at 9. 7x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, InMode Ltd. is actually cheaper at 9. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: InMode Ltd. wins at 0. 97x versus Intuitive Surgical, Inc. 's 2. 01x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — AIRS or INMD or SKIN or NVCR or ISRG?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +58. 7%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AIRS or INMD or SKIN or NVCR or ISRG?
By beta (market sensitivity over 5 years), Intuitive Surgical, Inc.
(ISRG) is the lower-risk stock at 1. 02β versus AirSculpt Technologies, Inc. 's 3. 37β — meaning AIRS is approximately 231% more volatile than ISRG relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
05Which is growing faster — AIRS or INMD or SKIN or NVCR or ISRG?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -77. 4% for AirSculpt Technologies, Inc.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AIRS or INMD or SKIN or NVCR or ISRG?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AIRS or INMD or SKIN or NVCR or ISRG more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, InMode Ltd. (INMD) is the more undervalued stock at a PEG of 0. 97x versus Intuitive Surgical, Inc. 's 2. 01x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, InMode Ltd. (INMD) trades at 9. 6x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 34. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.
08Which pays a better dividend — AIRS or INMD or SKIN or NVCR or ISRG?
In this comparison, AIRS (0.
1% yield) pays a dividend. INMD, SKIN, NVCR, ISRG do not pay a meaningful dividend and should not be held primarily for income.
09Is AIRS or INMD or SKIN or NVCR or ISRG better for a retirement portfolio?
For long-horizon retirement investors, Intuitive Surgical, Inc.
(ISRG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02), +554. 2% 10Y return). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ISRG: +554. 2%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AIRS and INMD and SKIN and NVCR and ISRG?
These companies operate in different sectors (AIRS (Healthcare) and INMD (Healthcare) and SKIN (Consumer Defensive) and NVCR (Healthcare) and ISRG (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: AIRS is a small-cap quality compounder stock; INMD is a small-cap deep-value stock; SKIN is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.